Search

Your search keyword '"Lipton, Allan"' showing total 960 results

Search Constraints

Start Over You searched for: Author "Lipton, Allan" Remove constraint Author: "Lipton, Allan"
960 results on '"Lipton, Allan"'

Search Results

3. Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types

4. Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers

5. Beyond October, Beyond Pink: A Year-Round Revelation for Women's Breast Health

6. Cancer and Bone: Historical Perspective

8. The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis

9. Supplementary Figures S1 and S2 and Supplementary Tables S1 and S2 from Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents

10. Allan Lipton_Conflict of Interest Form from Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents

12. Data from Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

13. Supplementary Data from Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

14. CCR Translation for This Article from Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

15. Supplementary Figures 1-2, Methods from Lactoferrin–Endothelin-1 Axis Contributes to the Development and Invasiveness of Triple-Negative Breast Cancer Phenotypes

16. Supplementary Figure 3 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

17. Supplementary Figure 2 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

18. Supplementary Figure 1 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

19. Supplementary Figure Legends 1-5 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

20. Supplementary Figure 4 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

21. Data from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

22. Supplementary Methods from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

23. Supplementary Table 1 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

24. Supplementary Figure 5 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

25. Supplementary Table 2 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

26. Data from Lactoferrin–Endothelin-1 Axis Contributes to the Development and Invasiveness of Triple-Negative Breast Cancer Phenotypes

27. New Targeted Therapies for Bone Metastases

31. Circulating HER2/neu : Clinical Utility

32. Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment with or without chemotherapy in high-risk, stage IVA/B NSCLC.

34. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

41. Abstract P5-13-10: Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2- metastatic breast cancer patients

43. Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

45. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

48. Contributors

Catalog

Books, media, physical & digital resources